Patel Moosa, Philip Vinitha, Fazel Fatima
Division of Clinical Haematology, Department of Medicine, Chris Hani Baragwanath Hospital and the University of the Witwatersrand, P.O. Box 96092, Brixton, Johannesburg 2019, South Africa.
Adv Hematol. 2011;2011:578163. doi: 10.1155/2011/578163. Epub 2011 Feb 8.
Hodgkin's lymphoma (HL) occurs with increasing frequency in human-immunodeficiency-virus-(HIV-) infected individuals. The natural history and behaviour of HIV-HL is different, being more atypical and aggressive. The association between HIV and HL appears to be primarily EBV driven. HAART use does not significantly impact on the incidence of HL. Indeed, the risk of HL has increased in the post-HAART era. However, the advent of HAART has brought renewed hope, allowing standard therapeutic options to be used more optimally, with better treatment outcomes. Despite the renewed optimism, the overall survival of HIV-HL patients remains less favourable than that in HIV-seronegative patients. This is particularly true in sub-Saharan Africa, where there is a significant burden of HIV/AIDS and where more than half the patients are HAART naive at diagnosis of HL. The similarities and differences of a South African cohort of HIV-HL are presented in this paper.
霍奇金淋巴瘤（HL）在人类免疫缺陷病毒（HIV）感染个体中的发病率呈上升趋势。HIV相关HL的自然病程和行为有所不同，更具非典型性和侵袭性。HIV与HL之间的关联似乎主要由EB病毒驱动。使用高效抗逆转录病毒疗法（HAART）对HL的发病率没有显著影响。事实上，在HAART时代之后，HL的风险有所增加。然而，HAART的出现带来了新的希望，使标准治疗方案能够得到更优化的使用，从而获得更好的治疗效果。尽管重新燃起了乐观情绪，但HIV相关HL患者的总体生存率仍低于HIV血清阴性患者。在撒哈拉以南非洲地区尤其如此，那里有大量的HIV/AIDS负担，超过一半的患者在诊断HL时未接受过HAART治疗。本文介绍了南非一组HIV相关HL患者的异同情况。
